방사선종양학

본문글자크기
  • [Radiother Oncol.] A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8 + cells in locally advanced rectal cancer

    [Radiother Oncol.] A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8 + cells in locally advanced rectal cancer

    서울의대 / 전승혁, 임유진, 지의규*

  • 출처
    Radiother Oncol.
  • 등재일
    2021 Sep
  • 저널이슈번호
    162:124-131. doi: 10.1016/j.radonc.2021.07.004. Epub 2021 Jul 12.
  • 내용

    바로가기  >

    Abstract
    Background and purpose: Regarding the altered tumor immune status following cytotoxic treatment, this study aims to develop a radiomic signature to predict CD8+ tumor-infiltrating lymphocyte (TIL) density changes in chemoradiotherapy (CRT) of rectal cancer.

    Materials and methods: We used the magnetic resonance imaging (MRI) and immunohistochemistry data before and after neoadjuvant CRT. The discovery datasets consisted of pre-CRT dataset A1 (n = 113), post-CRT datasets A2 (n = 32; predominance of tumor) and A3 (n = 20; pure fibrosis). The developed model was validated in dataset B (n = 28). Thirty-eight radiomic features from T2-weighted MRI scans were incorporated into the least absolute shrinkage and selection operator method.

    Results: In pre-CRT dataset A1, the area under the receiver operating characteristic curve (AUC) values of radiomic score for predicting CD8+ TILs were 0.760 and 0.729 for training and validation subsets, respectively. A significant correlation was observed between the signature and CD8+ TIL density in the post-CRT dataset A2 (Pearson's R = -0.372, P = 0.036), whereas no association was found in dataset A3 (Pearson's R = -0.069, P = 0.77). The association was also observed in the validation dataset B (Pearson's R = -0.374, P = 0.049). In dataset A2, the radiomic score difference predicted changes in CD8+ TIL density (AUC = 0.824).

    Conclusion: We established the MRI-derived radiomic signature for predicting CRT-induced alterations in CD8+ TILs. This study suggests the clinical utility of radiomics-immunophenotype modeling to evaluate tumor immune status following neoadjuvant chemoradiation in rectal cancer.

     

     

     

    Affiliations

    Seung Hyuck Jeon 1, Yu Jin Lim 2, Jaemoon Koh 3, Won Ick Chang 4, Sehui Kim 3, Kyubo Kim 5, Eui Kyu Chie 6
    1Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
    2Department of Radiation Oncology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea.
    3Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
    4Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
    5Department of Radiation Oncology, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
    6Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea; Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea. Electronic address: ekchie93@snu.ac.kr.

  • 키워드
    CD8-positive T-lymphocytes; Chemoradiotherapy; Neoadjuvant therapy; Radiomic score; Radiomics; Rectal neoplasms. Copyright © 2021 Elsevier B.V. All righ
  • 연구소개
    최근 종양에 침투한 면역세포, 특히 CD8 T 세포의 중요성이 대두되고 있습니다. 국소진행된 직장암 환자에서 전통적으로 시행하는 수술 전 동시 항암 방사선요법으로 종양 내 CD8 T 세포가 증가할 수 있다는 사실이 밝혀진 바 있습니다. 본 연구에서는 직장암 환자가 통상적으로 촬영하는 MRI에서 radiomics 분석으로 종양의 영상 정보를 추출하여 수술 전, 수술 후 CD8 T 세포의 침윤 정도 및 그 차이를 예측할 수 있는 모델을 구축했습니다. 이는 치료에 따른 CD8 T 세포의 양을 비침습적으로 추적할 가능성을 열어준 연구입니다.
  • 덧글달기
    덧글달기
       IP : 3.236.138.35

    등록